Similarly, polymorphisms in the PD-L1 gene, such as rs822336 and rs2297136, have been found to affect responses to PD-1/PD-L1 blockade therapies, particularly in NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.